Open AccessAlopecia With Endocrine Therapies in Patients With Cancer
Author(s) -
Saggar Vishal,
Wu Shenhong,
Dickler Maura N.,
Lacouture Mario E.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0193
Subject(s) - medicine , exemestane , anastrozole , tamoxifen , oncology , enzalutamide , fulvestrant , dysgeusia , toremifene , prostate cancer , breast cancer , adverse effect , incidence (geometry) , cancer , androgen receptor , physics , optics
Learning ObjectivesDefine the incidence and grades of alopecia to endocrine‐based therapies in cancer patients. Differentiate risk of alopecia to various endocrine agents used against cancer. Design therapeutic, counseling, and supportive care strategies for patients requiring endocrine agents causing alopecia.